Peer support workers and people diagnosed with schizophrenia want a real say in how mental health research is chosen and run, according to a 2026 German interview study. They valued medication and brain research, but no more than research on therapy, relationships and everyday care.1 Research Highlights 26 interviews, 21 voices on research: researchers interviewed …
A 37-question survey that maps what a family caring for someone with schizophrenia has to work with, from money and emotional support to community services, held together well in its first full test with 304 caregivers in Beijing.1 Research Highlights What was tested: the M-FRAT, a caregiver-rated questionnaire on family resources for schizophrenia, given to …
A 2026 German-Austrian cohort analysis found that people with schizophrenia who were taking quetiapine scored modestly higher on demanding working-memory tests than sex- and age-matched patients who were not, with the largest gap at doses of 300 mg a day or less.1 Because patients were not randomized to quetiapine, this is an association; the advantage …
At entry to US specialty clinics, 34% of 2,951 young people with first-episode psychosis reported suicidal thoughts and 7% had attempted suicide in the previous 6 months. A 2026 Early Psychosis Intervention Network (EPINET) analysis found odds fell 76% for thoughts and 85% for attempts over 2 years of care.1 With no comparison group, the …
A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean difference, or SMD, of −0.75), paliperidone (−0.62), and olanzapine (−0.60) vs. placebo.1 Confidence in every comparison was low or very low, the top 3 were not statistically separable, and most …
A 2026 case report described valproate 800 mg/day improving agitation in residual-phase treatment-resistant schizophrenia but being followed by hypoglycemia and pancytopenia; after discontinuation, lithium 600 mg/day at 0.8 mEq/L was associated with BPRS improvement from 80 to 64.1 The calibrated read is mixed: valproate looked behaviorally useful in 1 patient, but the safety signal was …
A 2026 randomized study involving 80 people with schizophrenia found that adding high-frequency repetitive transcranial magnetic stimulation to risperidone improved PANSS cognitive-factor scores and aggressive-behavior ratings more than risperidone alone over 4 weeks.1 Research Highlights Design was randomized but short: 80 patients were assigned to risperidone alone or risperidone plus rTMS, 40 per group, with …